These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 19667597)

  • 1. The power of statins: aggressive lipid lowering.
    Jones PH
    Postgrad Med; 2002 Oct; 112(4 Suppl):23-30. PubMed ID: 19667597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for aggressive lipid lowering in high-risk patients.
    Cohen JD
    J Am Osteopath Assoc; 2011 Apr; 111(4 Suppl 3):eS7-12. PubMed ID: 21593473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?
    Rana JS; Boekholdt SM
    Curr Opin Cardiol; 2010 Nov; 25(6):622-6. PubMed ID: 20852414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid management with statins. The lower the better?
    Laufs U; Liao JK; Böhm M
    Z Kardiol; 2004 Jan; 93(1):4-9. PubMed ID: 14740235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Coronary heart disease prevention. Are there differences in cholesterol synthesis inhibitors?].
    Müller-Wieland D; Faust M; Schleifenbaum T; Krone W
    MMW Fortschr Med; 2000 Jul; 142(30):26-8. PubMed ID: 10955015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel therapeutic approach to dyslipidemia.
    Clearfield MB
    J Am Osteopath Assoc; 2003 Jan; 103(1 Suppl 1):S16-20. PubMed ID: 12572626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based prediction of statin use with lipid-panel data from the National Health and Nutrition Examination Survey.
    Gorevski E; Bian B; Kelton CM; Martin Boone JE; Guo JJ
    Value Health; 2012 Jan; 15(1):32-8. PubMed ID: 22264969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing face of dyslipidemia therapy.
    Banerjee AK
    Indian Heart J; 2008; 60(3):192-4. PubMed ID: 19240305
    [No Abstract]   [Full Text] [Related]  

  • 11. [Statins--attaining goal values--with reference to recent studies].
    Toplak H; Schallmoser K; DeCampo A
    Wien Med Wochenschr; 1999; 149(5-6):144-5. PubMed ID: 10408006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying patients for aggressive cholesterol lowering: the risk curve concept.
    Robinson JG; Stone NJ
    Am J Cardiol; 2006 Nov; 98(10):1405-8. PubMed ID: 17134640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
    Goumas GS
    Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins targeting inflammation by lowering low-density lipoprotein?
    Tuzcu EM; Nicholls SJ
    J Am Coll Cardiol; 2007 May; 49(20):2010-2. PubMed ID: 17512356
    [No Abstract]   [Full Text] [Related]  

  • 15. Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors.
    Chuang P; Langone AJ
    Am J Ther; 2007; 14(5):438-41. PubMed ID: 17890931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study).
    Wiviott SD; Mohanavelu S; Raichlen JS; Cain VA; Nissen SE; Libby P
    Am J Cardiol; 2009 Jul; 104(1):29-35. PubMed ID: 19576317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure.
    Sueta CA; Massing MW; Chowdhury M; Biggs DP; Simpson RJ
    J Card Fail; 2003 Feb; 9(1):36-41. PubMed ID: 12612871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines.
    Mann D; Reynolds K; Smith D; Muntner P
    Ann Pharmacother; 2008 Sep; 42(9):1208-15. PubMed ID: 18648016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL.
    Shah PK
    Curr Opin Cardiol; 2010 Nov; 25(6):603-8. PubMed ID: 20827180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do statins decrease cardiovascular disease at the expense of increasing cancer?
    Goldstein MR; Mascitelli L
    Int J Cardiol; 2009 Apr; 133(2):254-5. PubMed ID: 18164769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.